Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in analyst-led fireside chats at the following three healthcare conferences: 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th at 8:30AM ET.

GlobeNewsWire • May 13, 2026

DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates

DOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA Contends This Conduct Constitutes a Failure of the Board's Duty of Care Maintains the Company should remove its CEO and Explore a Strategic Sale of the Company Instead of Pursuing Risky Litigation Asserts Pacira Will Continue its Value-Destroying Behavior Unless Changes are Made to the Board; DOMA's Nominees Will Bring Relevant Expertise in Risk Management and Commitment to Stockholder Value to Realign the Board with Shareholders' Interests and Creating Certainty in Outcomes Instead of Gambling with the Company's Future MIAMI, May 13, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perpetual"), which, together with its affiliates (collectively, "DOMA" or "we"), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), has today sent a letter to the Company's stockholders outlining the rationale for urgently needed change in the composition of the Company's Board of Directors (the "Board") and emphasizing how DOMA's independent, experienced and highly qualified nominees would bring genuine independence to the Company's Board and support the much-needed maximization of stockholder value. In its letter, DOMA Perpetual asserts Management and the Board continue to promote a risky strategy of "bet the farm" litigation that has already likely cost the Company more than a third of future EXPAREL revenues in a prior settlement.

PRNewsWire • May 13, 2026

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has sent a letter to stockholders in connection with its upcoming 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on June 9, 2026.

GlobeNewsWire • May 12, 2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on May 4, 2026 to ten new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

GlobeNewsWire • May 8, 2026

Pacira BioSciences Mails Letter to Stockholders

Details Success of Pacira's 5x30 Strategy and Solid First Quarter 2026 Results  Reiterates Board's Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has mailed a letter to stockholders in connection with the Company's 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on June 9, 2026.

GlobeNewsWire • May 5, 2026

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

SASKATOON, Saskatchewan, May 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, is pleased to announce the completion of its acquisition from an arm's length vendor (the “Vendor”) of the prescription files, patient records and related operational data (collectively, the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp's existing PharmaChoice-bannered pharmacies in Western Canada (the “Acquisition”). The purchase price for the Acquisition was $300,000, subject to customary adjustments, and was satisfied with cash on hand. No finder's fees were payable in connection with the Acquisition.

GlobeNewsWire • May 1, 2026

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.

Zacks Investment Research • May 1, 2026

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 1, 2026

PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update

SASKATOON, Saskatchewan, April 30, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, is pleased to announce that it has entered into definitive share purchase agreements, each dated April 28, 2026 (collectively, the “Agreements”) to acquire from two arm's length vendor groups (collectively, the “Vendors”) a 100 percent interest in eight PharmaChoice Canada bannered pharmacies located in Eastern Canada (the “Acquisitions”), representing a meaningful expansion of the Corporations geographical footprint and operating scale.

GlobeNewsWire • Apr 30, 2026

Pacira BioSciences Reports First Quarter 2026 Financial Results

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in Phase 3 registrational study of ZILRETTA in osteoarthritis pain of the shoulder; study on track for topline readout by end of year --

GlobeNewsWire • Apr 30, 2026